Tenpoint Therapeutics announced the submission of a New Drug Application (NDA) to the FDA for Brimochol ... Patients gained more than 15 letters on the ETDRS chart without clinically meaningful loss ...

Explore the impact of 3D models in drug discovery and how they enhance predictive insights in pre-clinical research.

"Final data from phase 2a study underscores potential for fostrox + Lenvima to become first approved option in second-line liver cancer" Financial summary for the quarterNet turnover amounted ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Fresenius Medical Care offers strong credit, a solid pipeline, but weak margins and limited short-term upside curb enthusiasm ...

Accuity, the market leader in clinical revenue cycle integrity for hospitals and health systems, is revolutionizing the healthcare revenue cycle with advanced technology that mimics and enhances the ...

Reinforces confidence in 5x30 plan - -- Continued focus on margin expansion and operational efficiency -- BRISBANE, Calif., April 17 ...

It’s no secret that drug development is a huge ... have the economic luxury of decades-long development cycles, indication expansion can provide new treatment avenues for patients with few ...

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, expectations were $2.58. Operator: Good morning, and welcome to Johnson & ...

The Global AI Summit for Africa, held in Kigali, Rwanda from April 3-4, galvanized the continent's ambition to harness the transformative power of artificial intelligence (AI) for sustainable ...

Asia-Pacific omega-3 supplements Market is flourishing due to increasing consumer awareness of the health benefits associated with omega-3 fatty acids. Increased concerns about well-being, coupled ...

Tempus AI, Inc. TEM is scheduled to report first-quarter fiscal 2025 results on May 6. In the last reported quarter, the company’s adjusted loss of 18 cents was wider than the Zacks Consensus Estimate ...